Our Investor Proposition

Unlocking value for our shareholders

Valneva’s integrated business model is based on valuable commercial and R&D assets in important, high-value niches.

Stock Information

€ % Last update: January 1, 1970 at CET Stock Price

“We have made major corporate progress”

Valneva's CEO Thomas Lingelbach comments on the first half of 2020

HY Financial Results 2020

Valneva has published its HY Financial Results 2020 on August 4, 2020.

Upcoming Events

September 9, 2020

Citi Healthcare Conference

September 27, 2020

World Vaccine Congress Washington

H1 2020 Financial Results

Contact

Investor Relations Team

Campus Bio-Ouest
6, Rue Alain Bombard
44800 Saint-Herblain, France

T: +33 2 28 07 37 10 investors@valneva.com

Subscribe to Valneva News

Submit

Press Releases

August 6, 2020

Valneva Announces Appointment of Juan Carlos Jaramillo as Chief Medical Officer

August 4, 2020

Valneva Reports H1 Results Marked by Major Corporate Achievements and Strong Cash Position

July 22, 2020

Valneva Announces Positive Initial Results for Phase 2 Study of Lyme Disease Vaccine Candidate

View More